The crystal structure, i.e., polymorph, of active pharmaceutical ingredients (APIs) greatly impacts the key properties of the solid dosage drugs, however, the crystallization behavior of the polymorphs and their interplay with the molecular level structure is complex and difficult to understand. Improved understanding has been obtained by investigating the crystallization of two model APIs, piroxicam and isonicotinamide, both can forms polymorphs with different hydrogen bonding and molecular orientation.
The experimental results suggested that initial concentration plays a major role in determining the produced polymorphic form of the API. The results also shows the importance of including more parameters for polymorphic control models, especially for compounds with big differences in hydrogen bonding network and molecular orientations.
Recent publications:
T.B. Hansen, T. Taris, B.-G. Rong, M. Grosso and H. Qu, Polymorphic behavior of isonicotinamide in cooling crystallization from various solvents, Journal of Crystal Growth, Vol. 450 (2016), 81-90.
T.B. Hansen and H. Qu, Formation of piroxicam polymorphism in solution crystalliation: effect and interplay of operation parameters, Crystal Growth & Design, Vol. 15 (2015), 4694-4700.
For more information please contact Associate Professor Haiyan Qu